Erratum: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Alexion Pharmaceuticals, Inc., 352 Knotter Drive, Cheshire, Connecticut 06410, USA.
Nature Biotechnology (Impact Factor: 41.51). 12/2007; 25(11):1256-64. DOI: 10.1038/nbt1344
Source: PubMed

ABSTRACT The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.

Download full-text


Available from: Robert Brodsky, Aug 14, 2014
35 Reads
  • Source
    • "We detected comparable avidities for mAb 1340, A233 and A235 with half maximal effective concentrations (EC50) of 0.16 nM, 0.07 nM and 0.1 nM, respectively. The described antibodies showed similar binding strengths as an established anti-complement mAb Eculizumab (anti-C5 mAb, 0.12 nM) and even a higher mAb-antigen interaction as the routinely used therapeutic mAb Bevacizumab (anti-VEGF, 0.8 nM) [52], [53]. In consideration of a broad affinity range from 1 pM to 1 nM of therapeutic antibodies the newly described mAb 1340 displays a high avidity towards properdin [54]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The complement system is an essential part of the innate immune system by acting as a first line of defense which is stabilized by properdin, the sole known positive regulator of the alternative complement pathway. Dysregulation of complement can promote a diversity of human inflammatory diseases which are treated by complement inhibitors. Here, we generated a novel blocking monoclonal antibody (mAb) against properdin and devised a new diagnostic assay for this important complement regulator. Mouse mAb 1340 specifically detected native properdin from human samples with high avidity. MAb 1340 inhibited specifically the alternative complement mediated cell lysis within a concentration range of 1-10 µg/mL. Thus, in vitro anti-properdin mAb 1340 was up to fifteen times more efficient in blocking the complement system as compared to anti-C5 or anti-Ba antibodies. Computer-assisted modelling suggested a three-dimensional binding epitope in a properdin-C3(H2O)-clusterin complex to be responsible for the inhibition. Recovery of properdin in a newly established sandwich ELISA using mAb 1340 was determined at 80-125% for blood sample dilutions above 1∶50. Reproducibility assays showed a variation below 25% at dilutions less than 1∶1,000. Systemic properdin concentrations of healthy controls and patients with age-related macular degeneration or rheumatic diseases were all in the range of 13-30 µg/mL and did not reveal significant differences. These initial results encourage further investigation into the functional role of properdin in the development, progression and treatment of diseases related to the alternative complement pathway. Thus, mAb 1340 represents a potent properdin inhibitor suitable for further research to understand the exact mechanisms how properdin activates the complement C3-convertase and to determine quantitative levels of properdin in biological samples.
    PLoS ONE 05/2014; 9(5):e96371. DOI:10.1371/journal.pone.0096371 · 3.23 Impact Factor
  • Source
    • "Eculizumab (h5G1.1-mAb) is a humanized monoclonal antibody (mAb) [43] derived from the murine anti-human C5 mAb; it binds to the complement component 5 (C5) and inhibits its further cleavage into C5a and C5b, disabling the progression to the terminal effector complement MAC [44]. Initial translation plans for eculizumab (Soliris®, Alexion Pharmaceuticals) started in autoimmune diseases; however, given its well-proven complement-mediated pathophysiology, PNH was subsequently identified as the best disorder for investigating this first complement inhibitor in humans. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The treatment of paroxysmal nocturnal hemoglobinuria (PNH) has been drastically changed by the introduction of the first therapeutic complement inhibitor eculizumab: 13 years of clinical experience have clearly proven that clinical complement inhibition is feasible, safe and potentially effective. At the same time, a number of observations have been collected showing that current anti-complement treatment is suitable for further improvements, especially for PNH, where extravascular hemolysis secondary to the activation of early complement has emerged as a novel unmet clinical need.Areas covered: Here we discuss publicly available information on second generation of complement therapeutics, which are currently in preclinical or clinical investigations. These agents are characterized by a broad target spectrum, since they inhibit the complement cascade at different levels: indeed, they include agents targeting component 5 as the key event of the terminal effector complement, as well as compounds designed to intercept the early steps of complement activation.Expert opinion: The field of therapeutic complement inhibition is growing rich with the development of several agents; the most promising approaches have already started their clinical development. It is conceivable that in the near future some of these strategies may offer improved therapeutic options for PNH and other complement-mediated human disorders.
    02/2014; 8(6):43-52. DOI:10.1517/21678707.2015.1041376
  • Source
    • "Recently, treatment of allograft recipients with eculizumab was reported to inhibit the cleavage of component C5 of the complement system [93, 94]. The use of this drug significantly decreased episodes of AMR in patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antibody-mediated rejection (AMR) is highly detrimental to the prolonged survival of transplanted kidneys. C4d has been regarded as a footprint of AMR tissue damage, and the introduction of C4d staining in daily clinical practice aroused an ever-increasing interest in the role of antibody-mediated mechanisms in allograft rejection. Despite the general acceptance of the usefulness of C4d in the identification of acute AMR, the data for C4d staining in chronic AMR is variable. The presence of C4d in the majority of the biopsies with features of chronic antibody-mediated rejection is reported, but this rejection without C4d staining is observed as well, suggesting that C4d is specific but not sensitive. Further studies on AMR with positive C4d staining in biopsy specimens are really important, as well as the study of novel routine markers that may participate in the pathogenesis of this process.
    Clinical and Developmental Immunology 07/2013; 2013:678180. DOI:10.1155/2013/678180 · 2.93 Impact Factor
Show more